ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financi...( EXTON Pa. Oct. 30 /- ViroPharma I...),Health

EXTON, Pa., Oct. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter and nine-months ended September 30, 2007.

Key events since June 30, 2007 include:

Clinical:

-- Patient enrollment began in a Phase 3 study of Camvia(TM) (maribavir)

in liver transplant patients;

-- Patient enrollment continued to the plan in Phase 3 study of Camvia in

stem cell transplant patients; study enrollment expanded to European

sites;

-- Dosing with HCV-796 was discontinued in an ongoing Phase 2 combination

study in hepatitis C patients following discovery of elevated liver

enzyme levels in a subset of patients; trial participants continue to

receive pegylated interferon and ribavirin in this study; and

-- New data presented at the 2007 Interscience Conference on Antimicrobial

Agents and Chemotherapy (ICAAC) meeting by Genzyme Corporation show

Vancocin(R) is superior in clinical success to metronidazole and

Genzyme's experimental compound in patients with severe CDAD (Louie et

al., 2007).

Operational:

-- Net sales of Vancocin(R) were $51 million;

-- Launched new sales and marketing initiatives for Vancocin; and

-- Research and development expenses increased by 40 percent over the

third quarter of 2006, primarily driven by investments in Camvia.

Financial:

-- Operating income was $27.9 million;

-- Working capital increased by $31 million to $573 million;

-- Cash, cash equivalents and short-term investments grew to $552 million;

and

-- 11th consecutive quarter of cash fl
'/>"/>